



10-25-04

1614

CASE TX/4-32304A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 48366860405</u> Express Mail Label Number	<u>October 22, 2004</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
PRESCOTT ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/00153

FILED: 9 JANUARY 2003

U.S. APPLICATION NO: 10/501,210

35 USC §371 DATE: 9 JULY 2004

FOR: DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND  
TREATMENT OF VASCULAR DISEASES COMPRISING  
RAPAMYCIN AND DERIVATIVES THEREOF

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of the asterisked references were cited in the International Search Report and were forwarded by the International Bureau. Copies of the non-asterisked references cited which are U.S. patent and U.S. Patent application publications pursuant to the waiver of requirement under 37 CFR 1.98(a)(2)(i) issued in the Official Gazette dated August 5, 2003, are not provided. Copies of the remaining non-asterisked references are enclosed.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initiated PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7909

  
Thomas R. Savitsky  
Attorney for Applicants  
Reg. No. 31,661

Date: *October 22, 2004*

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
TX/4-32304A  
APPLICATION NO.  
10/501,210  
APPLICANT  
PRESCOTT ET AL.  
FILING DATE  
9 July 2004

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL (/KW/)		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/KW/	AA	6,273,913	8/14/01	Wright et al.	623	1.42	4/16/98
/KW/	AB	200/0027340	10/4/01	Wright et al.	623	1.15	6/4/01
/KW/	AC	* 2001/009351	10/11/01	Falotico et al.	604	103.02	5/7/01
/KW/	AD	2002/0007213	1/17/02	Falotico et al.	623	1.21	5/7/01
/KW/	AE	2002/0082680	6/27/02	Shanley et al.	623	1.16	9/7/01
/KW/	AF	2002/0123505	9/5/02	Mollison et al.	514	291	9/10/01
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/KW/	AM	1 236 478	9/4/02	EP			<input type="checkbox"/>	<input type="checkbox"/>
/KW/	AN	98/07415	2/26/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
/KW/	AO	* 01/87263	11/22/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
/KW/	AP	01/87342	11/22/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
/KW/	AQ	* 01/87372	11/22/01	WO			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/KW/	AR	* Sousa et al., "Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One Year Angiographic and Intravascular Ultrasound Follow-up", Circulation, Vol. 104, No. 17, pp. 2007-2011 (2001).
/KW/	AS	Morice et al., "A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization", N. Engl. J. Med., Vol. 346, No. 23, pp 1773-1780 (2002).
/KW/	AT	Suzuki et al., "Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine COronary Model", Circulation, Vol. 104, pp. 1188-1193 (2001).

EXAMINER /Kevin Weddington/ (03/26/2008)

DATE CONSIDERED 03/26/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.  
TX/4-32304A  
APPLICATION NO.  
10/501,210  
APPLICANT  
PRESCOTT ET AL.  
FILING DATE  
9 July 2004

Group



## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/KW/	BA	01/87373	11/22/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
/KW/	BB	01/87374	11/22/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
/KW/	BC	01/87376	11/22/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
/KW/	BD	01/87435	11/22/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
/KW/	BE	02/056790	7/25/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
/KW/	BF	02/065947	8/29/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	BG						<input type="checkbox"/>	<input type="checkbox"/>
	BH						<input type="checkbox"/>	<input type="checkbox"/>
	BI						<input type="checkbox"/>	<input type="checkbox"/>
	BJ						<input type="checkbox"/>	<input type="checkbox"/>
	BK						<input type="checkbox"/>	<input type="checkbox"/>
	BL						<input type="checkbox"/>	<input type="checkbox"/>
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>
	BR						<input type="checkbox"/>	<input type="checkbox"/>
	BS						<input type="checkbox"/>	<input type="checkbox"/>
	BT						<input type="checkbox"/>	<input type="checkbox"/>
	BU						<input type="checkbox"/>	<input type="checkbox"/>
	BV						<input type="checkbox"/>	<input type="checkbox"/>
	BW						<input type="checkbox"/>	<input type="checkbox"/>
	BX						<input type="checkbox"/>	<input type="checkbox"/>
	BY						<input type="checkbox"/>	<input type="checkbox"/>
	BZ						<input type="checkbox"/>	<input type="checkbox"/>
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>						
/Kevin Weddington/ (03/26/2008)				03/26/2008				

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
TX/4-32304A  
APPLICATION NO.  
10/501,210  
APPLICANT  
PRESCOTT ET AL.  
FILING DATE  
9 July 2004

Group



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/KW/	CA	Simonsen, "Cardiology Market Continues Rapid Growth on a Broad Technology Front", The BBI Newsletter, Vol. 22, No. 4, p. 73, 1049-4316 (1999) -- IAC-ACC-NO: 62279650.
/KW/	CB	"Drug-Coated Stent Blocks Restenosis; Brief Article", Marketletter, p. N/A, 0951-3175 (2000) -- IAC-ACC-NO: 68770167.
	CC	
	CD	
	CE	
	CF	
	CG	
	CH	
	CI	
	CJ	
	CK	
	CL	
	CM	
	CN	

EXAMINER

/Kevin Weddington/ (03/26/2008)

DATE CONSIDERED

03/26/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.